Novartis is cueing up a new indication in the US for its oral therapy for complement-mediated diseases – Fabhalta – after reporting new data with the drug in ultra-rare kidney disease C3 ...

This cautious position sizing reflects the fund’s substantial USD 50 billion asset base, which requires careful attention to liquidity when building positions. The team has handled sizing ...